Supernus Pharmaceuticals Inc. Sets New 1-Year High at $9.23 (SUPN)
Supernus Pharmaceuticals (NASDAQ:SUPN)’s share price reached a new 52-week high during trading on Tuesday, Analyst Ratings News reports. The stock traded as high as $9.23 and last traded at $9.16, with a volume of 641,172 shares traded. The stock had previously closed at $8.47.
A number of research firms have recently commented on SUPN. Analysts at Zacks downgraded shares of Supernus Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, January 15th. They now have a $8.80 price target on the stock. Finally, analysts at FBR & Co. initiated coverage on shares of Supernus Pharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $11.36.
Supernus Pharmaceuticals has a 52 week low of $4.45 and a 52 week high of $9.05. The stock’s 50-day moving average is $7.5 and its 200-day moving average is $6.97. The company’s market cap is $312.7 million.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.11. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $2.54 million. The company’s revenue for the quarter was up 1328.6% on a year-over-year basis. Analysts expect that Supernus Pharmaceuticals will post $-2.33 EPS for the current fiscal year.
Supernus Pharmaceuticals, Inc (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.